CRC 1213 - Pulmonary Hypertension and Cor Pulmonale
Collaborative Research Center 1213 - Pulmonary Hypertension and Cor Pulmonale
Duration: July 1, 2016 to June 30, 2020
Heart and lung diseases, including pulmonary hypertension (PH), are the leading causes of death and represent the highest socio-economic burden of all diseases worldwide. PH is a progressive disease of multifactorial etiology with poor prognosis, which affects up to 100 million people worldwide in its various subtypes. It is characterized by pathological inward remodeling and loss of patency of the lung vasculature. Being challenged with increased afterload, the right ventricle (RV) initially responds to PH with a beneficial “adaptive” hypertrophy, which is, however, often rapidly followed by “maladaptive” changes leading to right heart decompensation and failure, the ultimate cause of death in PH (cor pulmonale). The Collaborative Research Center (CRC) 1213 combines basic science approaches and bedside clinical research in an interactive network to elucidate the pathogenic sequelae underlying PH and cor pulmonale and to evaluate novel treatment concepts. The CRC is pursuing an integrated concept to understand the common pathophysiological processes and molecular mechanisms that underlie structural pulmonary vascular abnormalities as well as RV adaptation and maladaptation in PH. Prevention of the progression from RV adaptation to maladaptation may open new ways to prevent death from PH. The aim is to reverse remodeling events to regain physiological lung vascular structure and function and to develop RV-focused treatment concepts currently not available.